株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Progenra, Inc. の製品パイプライン分析

Progenra, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 317881
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Progenra, Inc. の製品パイプライン分析 Progenra, Inc. - Product Pipeline Review - 2015
出版日: 2015年06月30日 ページ情報: 英文 24 Pages
概要

Progenra, Inc.は米国に本社をおく創薬企業で、心血管系疾患、癌、炎症および中枢神経系障害における新薬候補物質の研究開発を行っています。

当レポートでは、Progenra, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Progenra, Inc.の基本情報

  • Progenra, Inc.の概要
  • 主要情報
  • 企業情報

Progenra, Inc.:R&Dの概要

  • 主な治療範囲

Progenra, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Progenra, Inc.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Progenra, Inc.:薬剤プロファイル

  • P-005091
  • Small Molecules for Cancer
  • Small Molecules to Inhibit IDOL for Hypercholesterolemia
  • Small Molecules to Inhibit Synoviolin/Hrd 1 for Rheumatoid Arthritis
  • Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis
  • Small Molecules to Inhibit USP8 for Cystic Fibrosis

Progenra, Inc.:パイプライン分析

  • 分子タイプ別

Progenra, Inc.:最新のパイプライン動向

Progenra, Inc.:開発休止中のプロジェクト

Progenra, Inc.:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07216CDB

Summary

Global Markets Direct's, 'Progenra, Inc. - Product Pipeline Review - 2015', provides an overview of the Progenra, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Progenra, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Progenra, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Progenra, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Progenra, Inc.'s pipeline products

Reasons to buy

  • Evaluate Progenra, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Progenra, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Progenra, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Progenra, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progenra, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Progenra, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Progenra, Inc. Snapshot
    • Progenra, Inc. Overview
    • Key Information
    • Key Facts
  • Progenra, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Progenra, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Progenra, Inc. - Pipeline Products Glance
    • Progenra, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Progenra, Inc. - Drug Profiles
    • P-0005091
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Cardiovascular Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Synoviolin/Hrd 1 for Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit USP8 for Cystic Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Progenra, Inc. - Pipeline Analysis
    • Progenra, Inc. - Pipeline Products by Target
    • Progenra, Inc. - Pipeline Products by Molecule Type
    • Progenra, Inc. - Pipeline Products by Mechanism of Action
  • Progenra, Inc. - Recent Pipeline Updates
  • Progenra, Inc. - Dormant Projects
  • Progenra, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Progenra, Inc., Key Information
  • Progenra, Inc., Key Facts
  • Progenra, Inc. - Pipeline by Indication, 2015
  • Progenra, Inc. - Pipeline by Stage of Development, 2015
  • Progenra, Inc. - Monotherapy Products in Pipeline, 2015
  • Progenra, Inc. - Preclinical, 2015
  • Progenra, Inc. - Discovery, 2015
  • Progenra, Inc. - Pipeline by Target, 2015
  • Progenra, Inc. - Pipeline by Molecule Type, 2015
  • Progenra, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Progenra, Inc. - Recent Pipeline Updates, 2015
  • Progenra, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Progenra, Inc. - Pipeline by Top 10 Indication, 2015
  • Progenra, Inc. - Pipeline by Stage of Development, 2015
  • Progenra, Inc. - Monotherapy Products in Pipeline, 2015
  • Progenra, Inc. - Pipeline by Top 10 Target, 2015
  • Progenra, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Progenra, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top